ArticleInfection2026
Impact of immunoadsorption on autoantibodies and physical performance in post-COVID patients: a prospective exploratory study of 18 participants.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAutoantibodies against β-adrenergic and muscarinic acetylcholine receptors are said to play a role in the pathophysiology of post-COVID syndrome. To date, only a limited number of studies have investigated the effectiveness of immunoadsorption. This prospective exploratory study investigates the effectiveness of immunoadsorption by assessing reductions in autoantibody levels and improvements in physical performance.
methodsIn a prospective exploratory clinical trial, 18 patients with post-COVID syndrome and elevated levels of antibodies against β1/β2-adrenergic receptors and/or M3/M4-muscarinic acetylcholine receptors were treated with a course of five consecutive immunoadsorption sessions. Clinical assessments, objective functional performance tests (e.g., step counters), laboratory parameters, and self-reported performance were performed during the study.
resultsA total of 15 women and 3 men were included in the study. Immunoadsorption was well tolerated. All participants showed a significant reduction in circulating antibodies against β1/β2-adrenergic receptors and M3/M4-muscarinic acetylcholine receptors; however, these levels returned to baseline within the following 3 to 6 months. Objective determinations of physical performance showed no significant improvement following immunoadsorption. Self-reported evaluation revealed a slight improvement in pain and fatigue. However, the correlation analysis failed to demonstrate a significant association between changes in autoantibody levels and subjectively perceived symptoms.
conclusionImmunoadsorption was safe and resulted in a short-term, significant reduction in measured autoantibodies. However, there were no improvements in objectively measured performance. Our results indicate that immunoadsorption is not an effective approach for patients with post-COVID syndrome.
Indexed as
Identifiers
42579064What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.